RVPHReviva Pharmaceuticals Holdings Inc.

$0.63
$0.07
(10.00%)
Today
Updated: 03:59 PM EDT
Mkt Cap$8.97M
Vol82,756.00
News
all
press releases
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
Zacks
News Placeholder
More News
News Placeholder
Why Did RVPH Stock Crash 40% In Pre-Market Today?
The company priced its $10 million offering at a 20% discount from Wednesday’s close.
Stocktwits
News Placeholder
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...
MarketBeat
News Placeholder
Why Did RVPH Stock Crash 50% Today?
The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.
Stocktwits
News Placeholder
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...
MarketBeat
News Placeholder
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...
MarketBeat
News Placeholder
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...
MarketBeat
News Placeholder
Brokers Offer Predictions for RVPH FY2025 Earnings
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...
MarketBeat
News Placeholder
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Zacks
News Placeholder
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday
Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.